Membrane Transporter Screening of Antipsychotics

Membrane Transporter Screening of Antipsychotics

Inquiry

Ace Therapeutics offers specialized transporter protein assemblies and custom transporter protein screening services that enable you to identify new transporter protein target compounds. We use robust transporter protein uptake and inhibition assays to rapidly and cost-effectively screen for interactions of new anti-psychotic molecular entities with transporter proteins.

Introduction of Membrane Transporter Screening of Antipsychotics

Transporter proteins are a specialized group of membrane proteins that facilitate the transport of a variety of substances (including essential nutrients, ions, neurotransmitters, cellular waste, and environmental toxins) across cell membranes. Neurotransmitter transporters control the utilization and recovery of neurotransmitters, and play an important role in the conduction of neurotransmitters in the brain and the maintenance of cerebral nerve function. They are also the main drug targets for the treatment of a variety of mental diseases, including depression, schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, and drug abuse, etc. It is of the great theoretical value for antipsychotic drug development to reveal the structural basis, protein interactions, regulatory mechanisms, physiological functions, and pathological significances of important membrane receptors transport and regulatory processes.

Fig. 1 Neurotransmitter transporters (NTTs) regulate the neurotransmitter signal.Fig. 1 Neurotransmitter transporters (NTTs) regulate the neurotransmitter signal. (Niello M, et al., 2014)

Membrane Transporter Screening Services

Based on the membrane transporter targets and requirements provided by our customers, Ace Therapeutics will analysis and formulate specific programs for membrane transporter screening of antipsychotics service and select targeted antipsychotics that meet the requirements. Unlike the conventional isotope labeling and complex fluorescent labeling methods used in the membrane transporter screening of antipsychotics, our screening technology platforms can cope with the challenges of low throughput, complex cell sorting process, and irreversible damage to cells during research. With an experienced team of scientists, researchers and technicians, we provide fast turnaround, high-quality experimental results, and data reports for worldwide customers at competitive prices. If you are interested in our services, please contact us for more detailed information.

Membrane Transporter Screening Process for Antipsychotics

  • Identify membrane transporter targets for antipsychotic drug screening and develop proprietary experimental protocols accordingly.
  • Construct large-scale compound libraries and membrane transporter screening models for antipsychotic drugs at biochemical, cellular and animal levels.
  • Score and evaluate compounds for efficacy, and obtain candidate compounds by statistical analysis.
  • Repeat the previous step to obtain antipsychotic drugs by membrane transporter screening.

Fig. 2 Membrane transporter screening process of antipsychotics.Fig. 2 Membrane transporter screening process of antipsychotics.

Advantages of Our Services

  • Coverage of major transporter proteins
  • Availability of various panels
  • Short turnaround time
  • Personalized custom screening program design
  • More extensive research on the target of membrane transporters
  • Less damage to cells during antipsychotic drug screening

Ace Therapeutics has specifically set up several technology platforms to address the structural complexity of multichannel transmembrane proteins to meet the needs of different applications. We have developed a full range of structurally stable and active full-length multichannel transmembrane proteins to facilitate antipsychotic drug development and mechanistic studies. If you are interested in this service, please make an inquiry to learn how we can support you in your project.

Reference

  1. Niello M, et al. Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends in Pharmacological Sciences. 2020, 41 (7): 446-463.

ENTER YOUR EMAIL HERE TO SUBSCRIBE

Enter your E-mail and receive the latest news from us

Copyright © Ace Therapeutics. All Rights Reserved.
Top